Anh Tuan Le
University of Colorado Anschutz · 190 works · 4,958 citations · h-index 25
Top works
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer
- Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
- The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
- Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
- Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion
- EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
- A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China
- Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
- An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
- Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
- ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
- Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
- Chronic exposure to benzene results in a unique form of dysplasia
- Integrating WHO 2001–2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): A case–case analysis of benzene exposure